Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 2/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28598539 | 0.98 | CPN1 (0.44) | CPN1CPB2SLC6A2SLC6A3SLC6A4 | |
| Acetic Acid SCHEMBL21994473 | 0.95 | CPN1 (0.45) | CPN1CPB2SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL9219750 | 0.87 | L3MBTL1 (0.41) | L3MBTL1ALOX15 | |
| SCHEMBL24239364 | 0.86 | CPN1 (0.38) | CPN1CPB2SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL21564359 | 0.84 | CPN1 (0.44) | CPN1CPB2SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL10589008 | 0.83 | SLC6A1 (0.46) | CPN1CPB2SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL16732371 | 0.83 | METAP2 (0.40) | SLC6A2SLC6A3SLC6A4L3MBTL1 | |
| SCHEMBL1009487 | 0.83 | L3MBTL1 (0.39) | L3MBTL1 | |
| Hydrochloric Acid SCHEMBL29890856 | 0.83 | CPN1 (0.42) | CPN1CPB2SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL14386506 | 0.83 | CPN1 (0.42) | CPN1CPB2SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12502393-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| US-20220031704-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-02-03 | — | — | US | disclosed |
| US-20220031704-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-02-03 | — | — | US | disclosed |
| EP-3887376-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | Topadur Pharma AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| CN-113166157-A | Novel double-acting mode soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020109354-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020109354-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2020-06-04 | — | — | WO | disclosed |
| US-4289772-A | PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 1981-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12502393-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | PDE9A, PDE2A, PDE5A | CPN1 1201/4885CPB2 1272/4885SLC6A2 1361/4885 |
| US-20220031704-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE9A, PDE5A, PDE2A | CPN1 1312/4885CPB2 1273/4885SLC6A2 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.